Large language models-enabled digital twins for precision medicine in rare gynecological tumors

Jakob Nikolas Kather, Md, MSc, Jacqueline Lammert, Nicole Pfarr, Leonid Kuligin, Sonja Mathes, Tobias Dreyer, Luise Modersohn, Patrick Metzger, Dyke Ferber, Jakob Nikolas Kather, Daniel Truhn, Lisa Christine Adams, Keno K. Bressem, Sebastian Lange, Kristina Schwamborn, Martin Boeker, Marion Kiechle, Ulrich A. Schatz, Holger Bronger, Maximilian Tschochohei

Introduction

Rare Gynecological Tumors (RGTs) represent a significant challenge in oncology due to their low incidence, which precludes large-scale randomized controlled trials. Consequently, clinical guidelines are often sparse, and patient outcomes remain poor. While Molecular Tumor Boards (MTBs) aim to provide precision medicine by matching patients to therapies based on genetic biomarkers, they are hindered by a "data bottleneck." Critical patient information and relevant clinical evidence are frequently trapped in unstructured formats, such as narrative clinical notes and a vast, ever-expanding body of medical literature.

Methodology: A Two-Tier LLM Workflow

To address this curation challenge, researchers developed a proof-of-concept system utilizing Large Language Models (LLMs) to construct "digital twins"—virtual representations of individual patients that integrate clinical and molecular data. The workflow employs a strategic two-tier architecture:

  1. Privacy-Preserving Local Extraction: A local instance of Gemma-2-27b-it was deployed within the hospital's secure environment. This model extracts sensitive data points—including diagnosis, biomarker status, and treatment history—from institutional Electronic Health Records (EHRs) without compromising patient privacy.
  2. Large-Scale Literature Synthesis: Gemini-1.5-Pro was utilized to process public medical literature. Its extensive context window allows for the efficient synthesis of hundreds of scientific publications and clinical trial records (e.g., from PubMed and ClinicalTrials.gov) to identify "patients like mine" and relevant off-label therapeutic options.

Results: Efficiency and Accuracy

The LLM-enabled pipeline demonstrated a transformative impact on data curation speed. For institutional EHR data, the automated approach was 6.3 times faster than manual extraction (8.69 minutes vs. 55 minutes per file). Literature curation saw a 2.8-fold increase in speed.

Beyond speed, the models maintained high levels of accuracy. The cloud-based model achieved a precision of 0.97 on literature extraction, while the local model reached 0.85 on complex, unstructured EHR data.

Performance metrics for LLM-based data extraction across different source files and data points.

Clinical Impact: Individualized Treatment Targets

The utility of the digital twin approach was validated through a cohort of 21 cases (7 institutional and 14 from literature). A notable success involved a 77-year-old patient with metastatic uterine carcinosarcoma (UCS). By shifting from an organ-centric to a biology-centric view, the system identified high PD-L1 expression and suggested pembrolizumab—an immunotherapy typically used in other cancer types.

The digital twin pipeline also identified several other potential biomarkers and corresponding treatments for this patient, providing a comprehensive map for individualized care.

Individualized treatment targets identified by the digital twin pipeline for Case 1, including biomarkers like HER2 and ER-alpha.

Following the recommendation for pembrolizumab, the patient achieved a sustained partial response lasting over 30 months, significantly outperforming the typical 1.8-month progression-free survival (PFS) associated with standard third-line treatments for UCS.

Discussion and Future Directions

While promising, the study identified areas for improvement, particularly in temporal reasoning. Extracting the exact timing of treatments and calculating PFS from fragmented notes remains challenging for current LLMs. Additionally, the reliance on English-centric models highlights a need for high-quality, language-specific medical LLMs to capture nuances in local medical dialects.

Future work will focus on integrating this pipeline into larger national networks, such as the German Network for Personalized Medicine (DNPM), to validate the predictive power of digital twins across a broader spectrum of rare cancers. By acting as a "curation accelerator," LLMs can empower clinicians to move beyond traditional protocols toward truly personalized, biomarker-driven oncology.

Summary updated

Abstract

Rare gynecological tumors (RGTs) present major clinical challenges due to their low incidence and heterogeneity. The lack of clear guidelines leads to suboptimal management and poor prognosis. Molecular tumor boards accelerate access to effective therapies by tailoring treatment based on biomarkers, beyond cancer type. Unstructured data that requires manual curation hinders efficient use of biomarker profiling for therapy matching. This study explores the use of large language models (LLMs) to construct digital twins for precision medicine in RGTs. Our proof-of-concept digital twin system integrates clinical and biomarker data from institutional and published cases (n=21) and literature-derived data (n=655 publications with n=404,265 patients) to create tailored treatment plans for metastatic uterine carcinosarcoma, identifying options potentially missed by traditional, single-source analysis. LLM-enabled digital twins efficiently model individual patient trajectories. Shifting to a biology-based rather than organ-based tumor definition enables personalized care that could advance RGT management and thus enhance patient outcomes.
BibTeX
@article{msc2025large,
  author = {Jakob Nikolas Kather, MD, MSc and Jacqueline Lammert and Nicole Pfarr and Leonid Kuligin and Sonja Mathes and Tobias Dreyer and Luise Modersohn and Patrick Metzger and Dyke Ferber and Jakob Nikolas Kather and Daniel Truhn and Lisa Christine Adams and Keno K. Bressem and Sebastian Lange and Kristina Schwamborn and Martin Boeker and Marion Kiechle and Ulrich A. Schatz and Holger Bronger and Maximilian Tschochohei},
  title = {{Large language models-enabled digital twins for precision medicine in rare gynecological tumors}},
  journal = {Npj Digit. Medicine},
  year = {2025},
  doi = {10.1038/s41746-025-01810-z},
}
Figure